Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Researchers at Columbia University Irving Medical Center have identified the specific neurons in mice brains that tell them ...

The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...

They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

GLP-1 receptor agonists work on GLP-1 receptors ... As a result, "the exact mechanism of the way these medications work is not fully established," he says. This isn’t the first study to find ...